* Soleno Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Soleno Therapeutics Inc is for a loss of 37 cents per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 2.8% in the last three months.
* Wall Street's median 12-month price target for Soleno Therapeutics Inc is $61.50, above its last closing price of $49.23.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.28 -0.27 -0.33 Missed -20.7
Sep. 30 2023 -0.57 -0.58 -0.95 Missed -64.7
Jun. 30 2023 -0.89 -0.83 -0.81 Beat 2
Mar. 31 2023 -0.73 -0.72 -0.88 Missed -21.4
Dec. -0.76 -0.80 -0.58 Beat 27.5
31 2022
Sep. 30 2022 -0.91 -0.76 Beat 16.5
Jun. 30 2022 -0.90 -0.90 Met 0
Mar. 31 2022 -0.75 -1.05 -1.08 Missed -2.9
This summary was machine generated May 3 at 11:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments